Methotrexate 25mg/mL Injection

Methotrexate 25mg/mL Injection is an injectable folate-antagonist medicine used in selected rheumatoid arthritis, severe psoriasis and cancer regimens. Injectable treatment has indication-specific schedules and must not be confused with a routine daily injection.
A trained healthcare professional administers the injection using the route and schedule selected for the exact presentation and indication. Low-dose arthritis or psoriasis treatment is usually weekly, whereas oncology schedules differ. Concentration and total container dose are distinct measurements.
Methotrexate interferes with folate-dependent cellular pathways. Low-dose treatment reduces inflammatory immune activity, while oncology regimens inhibit proliferation of susceptible rapidly dividing cells.
Nausea, mouth ulcers, fatigue, low blood counts, raised liver enzymes and injection-site discomfort can occur. Fever, unusual bruising, severe mucosal ulcers, dry cough or breathlessness needs urgent assessment.
Blood counts, kidney and liver function are monitored. Pregnancy is excluded because of fetal toxicity. Trimethoprim or co-trimoxazole can markedly increase marrow toxicity. Injectable products must not be assumed suitable for intrathecal use; preservative and presentation are critical.
Provides parenteral methotrexate when the intended treatment requires an injectable route or oral treatment is not suitable.
No. It is a concentration. The total amount depends on the volume present; for example, 25mg/mL in 2mL contains 50mg.
No. Low-dose methotrexate for inflammatory disease is generally weekly. Daily repetition can cause life-threatening toxicity.
No. Route suitability depends on the exact preparation, concentration and preservatives; an injection label does not establish intrathecal suitability.
No. It is a disease-modifying or cytotoxic medicine, not an immediate analgesic.
Changing from tablets to injection does not remove all folate-related adverse effects; supplementation remains part of some low-dose regimens.
Fever during methotrexate treatment can indicate infection or low white cells and needs prompt assessment.
Parenteral: administered by a route outside the digestive tract. Concentration: amount of medicine per unit volume. Cytotoxic: damaging or inhibiting rapidly dividing cells. Intrathecal: administration into the fluid space around the spinal cord; AR: Methotrexate 25mg/mL حقن; FR: Methotrexate 25mg/mL solution injectable; PT: Methotrexate 25mg/mL solução injetável; ES: Methotrexate 25mg/mL solución inyectable; RU: Methotrexate 25mg/mL раствор для инъекций; ID: Methotrexate 25mg/mL injeksi; VI: Methotrexate 25mg/mL thuốc tiêm; MS: Methotrexate 25mg/mL suntikan; TL: Methotrexate 25mg/mL iniksyon; ZH-SG: Methotrexate 25mg/mL 注射剂
International B2B Enquiry
Send a structured B2B enquiry for Methotrexate 25mg/mL Injection under Immunology Care. Global Medicines Export helps international buyers review product information, pack details, quantity requirements, destination-market needs, quotation support and export documentation coordination from India.
Product name, required strength or pack, expected quantity, destination country, buyer type and preferred manufacturer if any.
Availability, quotation support, documentation expectations and shipment-ready order communication can be reviewed before confirmation.
Commercial invoice, packing information, manufacturer details, batch details and supporting documents where applicable and available.
Product availability, quotation, and documentation support are coordinated for international B2B enquiries.
Methotrexate 25mg/mL Injection